Signal2026-08-11
ClinicalTrials.gov

[PHASE1] Genetically Engineered Cells (BAFFR-CAR T Cells) for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Lymphoblastic Lymphoma

Part of

Engineered T Cell Immunotherapy Advances